Study guide

9.2 Urinary Tract Infections (Uncomplicated, Complicated, Recurrent), Pyelonephritis & Microscopic Hematuria

ANCC Adult-Gerontology Primary Care Nurse Practitioner AGPCNP-BC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The AGPCNP-BC Examination: Blueprint, Format & Scoring

1.1 The AGPCNP-BC Blueprint, Exam Format, Scoring, Eligibility & Renewal

2 Chapter 2: Assessment Foundations & Lifespan Considerations

2.1 Comprehensive Health History, Symptom Analysis & Lifespan Variations 2.2 Physical Examination Techniques & Age-Related Physiological Changes 2.3 Functional Assessment (Katz ADL / Lawton IADL) & Frailty Syndromes 2.4 Psychosocial, Nutritional, Cognitive & Mental Health Screening Instruments 2.5 Health Screening Guidelines (USPSTF) & Adult Immunization Schedules (CDC/ACIP)

3 Chapter 3: Diagnostic Reasoning & Clinical Interpretation

3.1 Diagnostic Reasoning, Clinical Decision-Making & Differential Diagnosis Formulation 3.2 Routine & Specialized Laboratory Interpretation 3.3 Diagnostic Imaging, ECG Interpretation & Pulmonary Function Testing 3.4 Evidence-Based Testing, Pre-Test Probability & Choosing Wisely Principles

4 Chapter 4: Cardiovascular Disorders

4.1 Hypertension: 2025 AHA/ACC Guideline, Resistant HTN & Secondary HTN 4.2 Dyslipidemia & ASCVD Risk Calculation, Statin Therapy & Non-Statin Agents 4.3 Coronary Artery Disease, Stable Angina & Post-ACS Outpatient Management 4.4 Heart Failure (HFrEF/HFpEF), Atrial Fibrillation & Peripheral Vascular Disease

5 Chapter 5: Respiratory Disorders

5.1 Asthma: GINA 2026 Guidelines, Phenotypes, Stepwise Pharmacotherapy & Action Plans 5.2 COPD: GOLD 2026 Report, ABE Staging, Triple Inhalers & Exacerbations 5.3 Lower Respiratory Infections (CAP, Bronchitis), Pleural Disease & Solitary Pulmonary Nodules

6 Chapter 6: HEENT & Allergic/Immunologic Disorders

6.1 Eye & Vision Disorders in Adult-Gerontology Primary Care 6.2 Ear, Hearing & Vestibular Disorders 6.3 Nose, Sinus, Oropharyngeal & Oral Cavity Disorders 6.4 Allergic & Immunologic Disorders: Anaphylaxis, Urticaria, Angioedema & Immunodeficiency

7 Chapter 7: Endocrine & Metabolic Disorders

7.1 Type 2 Diabetes Mellitus: ADA Standards of Care, Pharmacotherapy & Microvascular Complications 7.2 Thyroid Disorders: Hypothyroidism, Hyperthyroidism, Thyroiditis & Nodules 7.3 Adrenal & Pituitary Disorders: Adrenal Insufficiency, Cushing's, Hyperaldosteronism & Hypopituitarism 7.4 Metabolic Bone Disease: Osteopenia, Osteoporosis (FRAX, DEXA) & Hyperparathyroidism

8 Chapter 8: Gastrointestinal & Hepatic Disorders

8.1 Upper GI Disorders: GERD, Barrett's Esophagus, PUD, H. pylori & Gastritis 8.2 Lower GI Disorders: Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD) & Diverticular Disease 8.3 Hepatobiliary Disorders: MASLD/MASH, Viral & Alcoholic Hepatitis, Cirrhosis & Cholelithiasis 8.4 Acute & Chronic Abdominal Pain Syndromes, GI Bleeding & Colorectal Cancer Screening

9 Chapter 9: Renal, Urological & Men's Health

9.1 Chronic Kidney Disease: KDIGO Staging, Albuminuria Management & Renoprotective Strategies 9.2 Urinary Tract Infections (Uncomplicated, Complicated, Recurrent), Pyelonephritis & Microscopic Hematuria 9.3 Men's Health: Benign Prostatic Hyperplasia, Prostatitis, Epididymitis & Erectile Dysfunction

10 Chapter 10: Musculoskeletal & Rheumatologic Disorders

10.1 Degenerative & Overuse Musculoskeletal Disorders: Osteoarthritis, Tendinopathies & Spine Disorders 10.2 Autoimmune Rheumatologic Disorders: Rheumatoid Arthritis, SLE, Polymyalgia Rheumatica & Giant Cell Arteritis 10.3 Crystal Arthropathies & Fibromyalgia: Gout, Pseudogout & Centralized Pain Syndromes

11 Chapter 11: Neurological & Psychiatric Disorders

11.1 Headaches (Migraine, Tension, Cluster) & Cranial Neuralgias 11.2 Cerebrovascular Disease, TIA, Peripheral Neuropathies & Movement Disorders (Parkinson's) 11.3 Mood & Anxiety Disorders: Major Depressive Disorder, Generalized Anxiety Disorder & PTSD 11.4 Substance Use Disorders: Alcohol, Tobacco, Opioids & Cannabis in Primary Care

12 Chapter 12: Dermatologic, Hematologic & Infectious Disease

12.1 Primary Dermatologic Lesions, Inflammatory Dermatoses & Cutaneous Malignancies 12.2 Common Infectious Diseases: Skin/Soft Tissue Infections, Tick-Borne Illnesses & Viral Syndromes 12.3 Sexually Transmitted Infections (STIs): CDC Guidelines, Screening & Partner Management 12.4 Hematologic Disorders: Anemias (Microcytic, Normocytic, Macrocytic), Leukopenia & Coagulopathies

13 Chapter 13: Geriatric Syndromes, Pharmacology & Palliative Care

13.1 The Geriatric 5Ms Framework, Multimorbidity & Polypharmacy Deprescribing 13.2 Beers Criteria 2023 Update & STOPP/START Prescribing Rules 13.3 Pharmacokinetics, Pharmacodynamics & Pharmacogenomics Across the Adult Lifespan 13.4 Dementia vs. Delirium vs. Depression: Differential Diagnostics & Management 13.5 Falls, Mobility Impairment, Pressure Injury Prevention & Palliative Care Transitions

14 Chapter 14: Gynecologic & Women's Health

14.1 Contraceptive Management, Emergency Contraception & Preconception Counseling 14.2 Perimenopause, Menopause & Hormone Replacement Therapy (HRT) 14.3 Gynecologic Infections (Vaginitis, PID), Abnormal Uterine Bleeding & Cervical Cancer Screening (USPSTF/ASCCP)

15 Chapter 15: Plan-of-Care Process: Behavior Change, Education & Care Coordination

15.1 Behavioral Change: Motivational Interviewing, Models & Theories 15.2 Patient Education, Shared Decision-Making, Referrals, Care Coordination & Plan Reassessment

16 Chapter 16: APRN Professional Practice, Ethics, Policy & Quality Improvement

16.1 APRN Scope of Practice, Consensus Model, Collaborative Practice & Credentialing 16.2 Bioethics, Informed Consent, Advance Directives & Surrogate Decision-Making 16.3 Environmental & Social Determinants of Health, Health Equity & Culturally Responsive Care 16.4 Evidence-Based Practice (EBP), Quality Improvement (QI) Methodologies & Healthcare Economics

9.2 Urinary Tract Infections (Uncomplicated, Complicated, Recurrent), Pyelonephritis & Microscopic Hematuria

Key Takeaways Explain This Topic AI

Acute Uncomplicated Cystitis occurs in healthy, non-pregnant, premenopausal females with normal urinary anatomy; first-line empiric antimicrobial regimens are Nitrofurantoin (100 mg BID x 5 days), TMP-SMX DS (1 tab BID x 3 days, if local resistance <20%), or Fosfomycin trometamol (3 g single oral dose).

Fluoroquinolones (Ciprofloxacin, Levofloxacin) should NOT be used as first-line agents for uncomplicated cystitis due to extensive FDA Black Box Warnings (tendon rupture, peripheral neuropathy, aortic dissection, QT prolongation) and should be reserved for acute pyelonephritis, complicated UTIs, or bacterial prostatitis.

Asymptomatic Bacteriuria (ASB; ≥10⁵ CFU/mL without symptoms) must NOT be screened or treated in the general population, elderly nursing home residents, diabetics, or catheterized patients; treatment is strictly mandatory only in pregnant individuals and patients undergoing invasive urologic procedures with mucosal trauma.

Acute Pyelonephritis is characterized by upper urinary tract inflammation (fever, chills, flank pain, costovertebral angle tenderness) and is distinguished from lower UTI on urinalysis by the pathognomonic presence of White Blood Cell (WBC) Casts.

Microscopic Hematuria is defined by the AUA as ≥3 RBCs/HPF on microscopic evaluation of a single properly collected clean-catch urine specimen; dipstick hematuria alone is insufficient and requires microscopic confirmation before initiating risk-stratified evaluation (renal ultrasound/CT urography and cystoscopy) to rule out urothelial malignancy.

Last updated: August 2026

Urinary Tract Infections (Uncomplicated, Complicated, Recurrent), Pyelonephritis & Microscopic Hematuria

Urinary tract infections (UTIs) represent one of the most prevalent bacterial infections encountered across primary care, urgent care, and long-term care settings. For the Adult-Gerontology Primary Care Nurse Practitioner (AGPCNP) , board certification demands precision in differentiating uncomplicated from complicated UTIs, adhering to strict antimicrobial stewardship guidelines (especially avoiding overtreatment of asymptomatic bacteriuria), implementing evidence-based therapies for recurrent UTIs in postmenopausal women, managing acute pyelonephritis, and executing rigorous diagnostic evaluations for microscopic hematuria in accordance with American Urological Association (AUA) risk-stratification guidelines.

1. Microbiology & Pathogenesis of Urinary Tract Infections

Primary Uropathogens Across Clinical Settings +-----------------------------------------------------------------------------+

  • | SPECTRUM OF UROPATHOGENS |
  • | |
  • | 1. UROPATHOGENIC ESCHERICHIA COLI (UPEC) |
  • | - Responsible for 75% to 95% of acute uncomplicated cystitis and |
  • | pyelonephritis; ~50% of complicated/hospital-acquired UTIs. |
  • | - Virulence factors: Type 1 fimbriae (mannose-sensitive; bind bladder |
  • | uroplakin), P-fimbriae (Gal-Gal binding; ascends to renal parenchyma)|
  • | |
  • | 2. STAPHYLOCOCCUS SAPROPHYTICUS |
  • | - Coagulase-negative, Novobiocin-resistant Gram-positive coccus. |
  • | - 5% to 15% of acute cystitis in young, sexually active females. |
  • | |
  • | 3. KLEBSIELLA PNEUMONIAE & ENTEROBACTER SPECIES |
  • | - Gram-negative bacilli; frequent in diabetics and complicated UTIs. |
  • | |
  • | 4. PROTEUS MIRABILIS |
  • | - Urease-producing Gram-negative rod (hydrolyzes urea to NH3 + CO2). |
  • | - Produces alkaline urine (pH > 7.5), driving precipitation of |
  • | magnesium ammonium phosphate -> STRUVITE (STAGHORN) CALCULI. |
  • | |
  • | 5. ENTEROCOCCUS FAECALIS & ENTEROCOCCUS FAECIUM |
  • | - Gram-positive cocci in pairs/chains; common in elderly men, post- |
  • | instrumentation, catheter-associated UTIs (CAUTI). |
  • | |
  • | 6. PSEUDOMONAS AERUGINOSA |
  • | - Non-fermenting Gram-negative bacillus; common in chronic indwelling |
  • | catheters, neurogenic bladder, urinary stents, and post-urologic sx. |
  • +-----------------------------------------------------------------------------+

2. Clinical Classification & Diagnostic Evaluation +-----------------------------------------------------------------------------+

  • | CLINICAL CLASSIFICATION OF URINARY TRACT INFECTIONS |
  • | |
  • | [ ASYMPTOMATIC BACTERIURIA ] [ ACUTE UNCOMPLICATED CYSTITIS ] |
  • | - Growth >= 10^5 CFU/mL in - Dysuria, frequency, urgency, suprapub |
  • | asymptomatic patient. pain in healthy non-pregnant female. |
  • | - DO NOT TREAT (Except pregnancy - No fever, no flank pain, normal tract.|
  • | and invasive urologic surgery!).- Empiric 1st-line Rx without culture. |
  • | |
  • | [ COMPLICATED UTI ] [ ACUTE PYELONEPHRITIS ] |
  • | - UTI in MEN, pregnancy, poorly - Upper tract infection: Fever, chills, |
  • | controlled DM, immunosuppressed, nausea/vomiting, CVA tenderness. |
  • | catheter (CAUTI), anatomic/ - Urinalysis hallmark: WBC CASTS. |
  • | functional obstruction, CKD. - Urine & blood cultures MANDATORY. |
  • | - Urine culture MANDATORY. - Extended 7-14 day targeted therapy. |
  • +-----------------------------------------------------------------------------+
  • Urinalysis Interpretation: Chemical Dipstick & Microscopic Analysis

Leukocyte Esterase (LE): Enzyme produced by lysed neutrophils reflecting pyuria . Sensitivity 75–95%, specificity 65–95% for UTI. ( > 5 – 10 WBCs/HPF > 5\text{--}10\text{ WBCs/HPF} > 5 – 10 WBCs/HPF on microscopy confirms pyuria).

Nitrites: Gram-negative enterobacteriaceae ( E. coli , Klebsiella , Proteus ) reduce dietary nitrates into nitrites.

High Specificity ( > 95 % >95\% > 95% ): A positive nitrite strongly confirms enterobacteriaceae presence.

Low Sensitivity (~50%): A negative nitrite does not rule out infection! False negatives occur with: Gram-positive uropathogens ( Enterococcus , Staphylococcus saprophyticus ), Pseudomonas , low dietary vegetable intake, or frequent bladder emptying preventing the required 4-hour incubation period.

Urine Microscopy:

WBCs: > 5 – 10 WBCs/HPF > 5\text{--}10\text{ WBCs/HPF} > 5 – 10 WBCs/HPF indicates pyuria/inflammation.

Epithelial Cells: > 5 squamous epithelial cells/HPF > 5\text{ squamous epithelial cells/HPF} > 5 squamous epithelial cells/HPF indicates significant perineal contamination; specimen must be repeated with proper midstream clean-catch technique.

White Blood Cell (WBC) Casts: Cylindrical molds of polymorphonuclear leukocytes formed in the distal tubules and collecting ducts. Pathognomonic hallmark of Acute Pyelonephritis / Renal Parenchymal Inflammation , definitively distinguishing upper from lower tract infection.

Asymptomatic Bacteriuria (ASB): Strict Guidelines for Clinical Restraint

Definition: Isolation of ≥ 10 5 Colony-Forming Units (CFU)/mL \ge 10^5\text{ Colony-Forming Units (CFU)/mL} ≥ 1 0 5 Colony-Forming Units (CFU)/mL of a single uropathogen in a voided urine specimen in a patient without any signs or symptoms referable to a UTI (no dysuria, frequency, urgency, suprapubic pain, fever, or leukocytosis).

Guideline-Directed Practice (IDSA / USPSTF): Screening and treating ASB provides no clinical benefit and increases adverse drug reactions, Clostridioides difficile colitis, and antimicrobial resistance in:

Premenopausal or postmenopausal non-pregnant women.

Diabetic individuals.

Elderly nursing home residents (pyuria + bacteriuria is present in > 30 – 50 % >30\text{--}50\% > 30 – 50% of institutionalized elderly; treating asymptomatic foul-smelling or cloudy urine is malpractice!).

Patients with spinal cord injuries or neurogenic bladders.

Patients with indwelling urinary catheters. +-----------------------------------------------------------------------------+

  • | THE ONLY TWO STRICT INDICATIONS TO TREAT ASYMPTOMATIC |
  • | BACTERIURIA |
  • | |
  • | 1. PREGNANT INDIVIDUALS |
  • | - Screen at 12 to 16 weeks gestation (or 1st prenatal visit). |
  • | - If positive (>= 10^5 CFU/mL), treat with 4-7 days of safe antibiotics |
  • | (e.g., Cephalexin, Amoxicillin-Clavulanate, Nitrofurantoin [avoid |
  • | in 1st trimester and near term at 36-42 weeks]). |
  • | - Rationale: Untreated ASB progresses to acute pyelonephritis in 20-40% |
  • | of pregnancies, triggering preterm labor, sepsis, and low birth wt. |
  • | |
  • | 2. PATIENTS UNDERGOING INVASIVE UROLOGICAL SURGERY |
  • | - Specifically procedures with anticipated mucosal trauma or bleeding |
  • | (e.g., Transurethral Resection of Prostate [TURP]). |
  • | - Screen and treat prior to procedure to prevent bacteremia and sepsis.|
  • +-----------------------------------------------------------------------------+
  • 3. Evidence-Based Antimicrobial Management
  • Acute Uncomplicated Cystitis (IDSA Guidelines)

In a non-pregnant, premenopausal female presenting with classic symptoms of lower cystitis without systemic features, empiric treatment without routine pre-treatment urine culture is appropriate.

Antibiotic Agent Dosage & Administration Duration Contraindications & Clinical Pearls

Nitrofurantoin Monohydrate / Macrocrystals (Macrobid) (First-Line) 100 mg 100\text{ mg} 100 mg orally twice daily with food 5 Days - Contraindicated if e G F R < 30 mL/min / 1.73 m 2 eGFR < 30\text{ mL/min}/1.73\text{ m}^2 e GFR < 30 mL/min /1.73 m 2 (fails to achieve therapeutic urinary concentrations; risk of peripheral neuropathy and pulmonary fibrosis).; - Highly effective against E. coli ; ineffective against Proteus and Pseudomonas .

Trimethoprim-Sulfamethoxazole (TMP-SMX DS) (First-Line) 1 Double-Strength tablet ( 160 / 800 mg 160/800\text{ mg} 160/800 mg ) orally twice daily 3 Days - Use ONLY if local E. coli resistance is < 20 % < 20\% < 20% and patient has no sulfa allergy.; - Risk of hyperkalemia, Stevens-Johnson syndrome, and hematologic toxicities.

Fosfomycin Trometamol (First-Line) 3 g 3\text{ g} 3 g single-dose sachet dissolved in 3–4 oz cold water 1 Dose - High compliance; lower clinical cure rate compared to 5-day nitrofurantoin.; - Broad activity against multi-drug resistant (MDR) and ESBL-producing E. coli .

Pivmecillinam (First-Line where available) 185 mg 185\text{ mg} 185 mg orally three times daily 3 to 5 Days - Extended-spectrum penicillin specific for Gram-negative uropathogens.

Oral Beta-Lactams (Amoxicillin-Clavulanate, Cefpodoxime, Cefdinir, Cephalexin) (Second-Line) Augmentin 500 / 125 mg 500/125\text{ mg} 500/125 mg BID; Cefpodoxime 100 mg 100\text{ mg} 100 mg BID 5 to 7 Days - Use only when first-line agents cannot be used.; - Inferior efficacy and higher rate of gastrointestinal adverse effects.

Warning

The Fluoroquinolone Black Box Warning Mandate: Fluoroquinolones (Ciprofloxacin, Levofloxacin, Ofloxacin) must NOT be prescribed for acute uncomplicated cystitis if other guideline-endorsed options are available. The FDA and IDSA issue severe warnings regarding disabling and potentially irreversible toxicities: tendonitis and tendon rupture (especially Achilles tendon) , peripheral neuropathy , CNS toxicities (hallucinations, seizures) , QT prolongation / torsades de pointes , aortic aneurysm rupture or dissection , and severe hypoglycemia . Reserve fluoroquinolones for acute pyelonephritis, complicated UTIs, and bacterial prostatitis.

Complicated Urinary Tract Infections (Including UTIs in Men)

Diagnostic Mandate: A pre-treatment Urine Culture and Susceptibility test is mandatory for all complicated UTIs.

UTI in Men: By definition, all UTIs in men are classified as complicated due to anatomical length, higher risk of structural obstruction (BPH, strictures), and potential prostatic parenchymal seeding.

Treatment Duration: 7 to 14 days (longer durations required if prostatitis cannot be excluded):

Outpatient oral therapy: Ciprofloxacin 500 mg 500\text{ mg} 500 mg BID × 7 – 10 days \times 7\text{--}10\text{ days} × 7 – 10 days , Levofloxacin 750 mg 750\text{ mg} 750 mg daily × 5 – 7 days \times 5\text{--}7\text{ days} × 5 – 7 days , or TMP-SMX DS 1 tab BID × 10 – 14 days \times 10\text{--}14\text{ days} × 10 – 14 days (adjusted based on culture results).

Acute Pyelonephritis Management Algorithm +-----------------------------------------------------------------------------+

  • | ACUTE PYELONEPHRITIS DECISION ALGORITHM |
  • | |
  • | [PATIENT WITH ACUTE PYELONEPHRITIS] |
  • | - Fever, Chills, Nausea, CVA Tenderness |
  • | - MANDATORY: Urine Culture + Blood Cultures |
  • | | |
  • | v |
  • | [EVALUATE CLINICAL SEVERITY & HOST FACTORS] |
  • | | |
  • | +----------------------------+----------------------------+ |
  • | | | |
  • | v v |
  • | [OUTPATIENT CANDIDATE] [INPATIENT ADMISSION] |
  • | - Mild/moderate illness - Sepsis / Shock |
  • | - Tolerating oral intake/meds - Intractable vomiting |
  • | - Reliable; compliant - Pregnancy |
  • | - Normal anatomy/immunity - Urinary obstruction |
  • | - High fever / failed OP|
  • | | | |
  • | v v |
  • | [ORAL ANTIMICROBIAL REGIMEN] [INTRAVENOUS THERAPY] |
  • | * Ciprofloxacin 500 mg BID x 7 d * IV Ceftriaxone 1-2g Q24H|
  • | * Levofloxacin 750 mg daily x 5 d * IV Piperacillin-Tazo |
  • | * TMP-SMX DS BID x 14 d (if sens) * IV Cefepime / Meropenem|
  • | (Note: If local FQ resistance >10%, - Step down to oral |
  • | administer initial dose of IV Ceftriaxone after 24-48 hr afebrile|
  • | 1g or Gentamicin in clinic first!). - Total: 10-14 days Rx. |
  • +-----------------------------------------------------------------------------+
  • 4. Recurrent UTIs in Women: Diagnostic & Preventative Strategies
  • Diagnostic Definition

Recurrent UTI (rUTI) is formally defined as ≥ 2 \ge 2 ≥ 2 culture-proven episodes of acute uncomplicated cystitis within a 6-month period , OR ≥ 3 \ge 3 ≥ 3 culture-proven episodes within a 12-month period .

Pathophysiological Drivers in Postmenopausal Women

In postmenopausal women, estrogen depletion results in atrophy of the vaginal and vulvovaginal epithelium. The loss of glycogen leads to a collapse in the population of protective hydrogen-peroxide-producing Lactobacilli , causing vaginal pH to rise from an acidic normal ( pH 3.8 – 4.5 \text{pH } 3.8\text{--}4.5 pH 3.8 – 4.5 ) to an alkaline state ( pH > 5.0 – 6.0 \text{pH} > 5.0\text{--}6.0 pH > 5.0 – 6.0 ). This allows colonization of the vaginal introitus and periurethral area by pathogenic enteric coliforms ( E. coli ). +-----------------------------------------------------------------------------+

  • | POSTMENOPAUSAL RECURRENT UTI PATHOPHYSIOLOGY |
  • | |
  • | [MENOPAUSE / ESTROGEN LOSS] |
  • | | |
  • | v |
  • | [Vaginal & Urethral Mucosal Atrophy] |
  • | | |
  • | v |
  • | [Depletion of Glycogen & Loss of Lactobacilli] |
  • | | |
  • | v |
  • | [Vaginal pH Increases to Alkaline (> 5.5)] |
  • | | |
  • | v |
  • | [Enteric Coliform Colonization of Periurethral Space] |
  • | | |
  • | v |
  • | [RECURRENT ASCENDING CYSTITIS & PYELONEPHRITIS] |
  • +-----------------------------------------------------------------------------+
  • Evidence-Based Non-Antimicrobial & Pharmacological Management

Topical Vaginal Estrogen Therapy (First-Line in Postmenopausal Women):

Formulations: Vaginal Estradiol cream (0.5–1.0 g twice weekly), Estradiol vaginal ring (Estring), or Estradiol vaginal tablets (Vagifem 10 mcg twice weekly).

Mechanism: Re-establishes normal thick stratified squamous epithelium, restores glycogen production, promotes Lactobacilli recolonization, lowers vaginal pH to < 4.5 <4.5 < 4.5 , and reduces recurrent UTI rates by 50% to 75% .

Systemic absorption is minimal; does not require concurrent progestin for endometrial protection.

Increased Hydration: Increasing daily water intake by 1.5 Liters/day 1.5\text{ Liters/day} 1.5 Liters/day in women with low baseline fluid intake reduces UTI recurrence by ≈ 50 % \approx 50\% ≈ 50% via mechanical bladder flushing.

Post-Coital Voiding & Behavioral Habits: Voiding immediately after sexual intercourse; avoiding spermicidal contraceptives and diaphragms (which kill Lactobacilli).

Methenamine Hippurate ( 1 g 1\text{ g} 1 g PO BID): Non-antibiotic urinary antiseptic hydrolyzed in acidic urine ( pH < 5.5 \text{pH} < 5.5 pH < 5.5 ) to form bactericidal formaldehyde ; effective for non-antibiotic prophylaxis without generating resistance.

Antimicrobial Prophylaxis (Last Resort):

Post-Coital Single-Dose Prophylaxis: For sexually active women with coitus-related recurrences (e.g., TMP-SMX SS 80 / 400 mg 80/400\text{ mg} 80/400 mg or Nitrofurantoin 50 mg 50\text{ mg} 50 mg single oral dose immediately post-coitus).

Continuous Low-Dose Prophylaxis: Daily low-dose Nitrofurantoin 50 mg 50\text{ mg} 50 mg or TMP-SMX SS for 6 to 12 months in refractory cases.

  • 5. Microscopic Hematuria: AUA / SUFU Risk Stratification & Diagnostic Workup
  • Diagnostic Definition of Microscopic Hematuria

According to the American Urological Association (AUA) and Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) guidelines, Microhematuria is formally defined as: ≥ 3 Red Blood Cells per High-Power Field (RBCs/HPF) on microscopic evaluation of a properly collected, clean-catch urine specimen. \mathbf{\ge 3\text{ Red Blood Cells per High-Power Field (RBCs/HPF)}}\text{ on microscopic evaluation of a properly collected, clean-catch urine specimen.} ≥ 3 Red Blood Cells per High-Power Field (RBCs/HPF) on microscopic evaluation of a properly collected, clean-catch urine specimen.

Important

Dipstick Hematuria vs. Microscopic Examination: A positive chemical urine dipstick for blood (detecting heme via pseudoperoxidase activity) has high sensitivity ( > 90 % >90\% > 90% ) but poor specificity ( 65 – 80 % 65\text{--}80\% 65 – 80% ) due to false positives from myoglobinuria, hemoglobinuria, povidone-iodine, or concentrated urine. A positive dipstick NEVER establishes the diagnosis of microhematuria. The AGPCNP must confirm the presence of ≥ 3 RBCs/HPF \ge 3\text{ RBCs/HPF} ≥ 3 RBCs/HPF on formal microscopic urinalysis before initiating an invasive or radiologic hematuria evaluation!

Step 1: Exclude Benign / Transient Etiologies

Before initiating a full hematuria workup, evaluate and exclude reversible non-malignant triggers:

Acute urinary tract infection (treat and repeat UA in 4–6 weeks to verify resolution).

Menstrual contamination (repeat UA mid-cycle).

Recent strenuous physical exercise / long-distance running (repeat UA in 2–3 weeks).

Recent sexual intercourse or minor genitourinary trauma.

Recent urological catheterization or instrumentation.

Step 2: Differentiate Glomerular vs. Non-Glomerular (Urological) Hematuria

Clinical Characteristic Glomerular Hematuria (Renal Parenchymal) Non-Glomerular / Urological Hematuria (Epithelial/Malignancy)

Urine Color Brown, "tea-colored", "cola-colored", or smoky. Bright red, pink, or frank clots.

RBC Morphology (Phase Contrast) Dysmorphic RBCs ( > 25 % >25\% > 25% dysmorphic) , Acanthocytes (ring-shaped with blebs/Mickey Mouse ears). Isomorphic RBCs (Normal uniform round discs) .

Urine Proteinuria Significant ( U A C R > 300 mg/g UACR > 300\text{ mg/g} U A CR > 300 mg/g or > 500 mg/24 hr > 500\text{ mg/24 hr} > 500 mg/24 hr ). Minimal or absent ( U A C R < 30 mg/g UACR < 30\text{ mg/g} U A CR < 30 mg/g ).

Urinary Casts Red Blood Cell (RBC) Casts , granular casts. Absent.

Associated Signs Elevated blood pressure, peripheral edema, rising Cr. LUTS, flank colic, palpable flank mass.

Primary Pathology IgA Nephropathy, Glomerulonephritis, Lupus, Vasculitis. Urothelial Carcinoma (Bladder/Ureter) , Renal Cell Carcinoma, BPH, Nephrolithiasis.

Clinical Action Prompt NEPHROLOGY Referral for Renal Biopsy . AUA Risk-Stratified UROLOGY Referral (Cystoscopy + Imaging) . +-----------------------------------------------------------------------------+

  • | URINE SEDIMENT CAST DIFFERENTIATION |
  • | |
  • | CAST TYPE PATHOGNOMONIC CLINICAL ASSOCIATION |
  • | ----------------------------------------------------------------------- |
  • | Red Blood Cell Casts Acute Glomerulonephritis / Glomerular Hematuria |
  • | White Blood Cell Casts Acute Pyelonephritis / Acute Interstitial Nephr. |
  • | Renal Tubular Cell Casts Acute Tubular Necrosis (ATN) / Ischemia / Toxins |
  • | "Muddy Brown" Casts Pathognomonic for Acute Tubular Necrosis (ATN) |
  • | Fatty Casts / Oval Fats Nephrotic Syndrome ("Maltese Cross" polarized) |
  • | Broad, Waxy Casts Advanced Chronic Kidney Disease / ESRD |
  • | Hyaline Casts Benign / Dehydration / Strenuous Exercise |
  • +-----------------------------------------------------------------------------+
  • Step 3: AUA Risk Stratification for Microhematuria & Guideline-Directed Evaluation

For patients with confirmed non-glomerular microhematuria ( ≥ 3 RBCs/HPF \ge 3\text{ RBCs/HPF} ≥ 3 RBCs/HPF ), risk-stratify for urothelial malignancy: +-----------------------------------------------------------------------------+

  • | AUA RISK STRATIFICATION FOR MICROHEMATURIA |
  • | |
  • | LOW RISK |
  • | - Women < 50 yrs, Men < 40 yrs |
  • | - Never smoker or < 10 pack-years |
  • | - 3 to 10 RBCs/HPF on microscopy |
  • | - No additional risk factors |
  • | ---> CLINICAL ACTION: Shared decision-making: Repeat UA in 6 months OR |
  • | Renal Ultrasound + Cystoscopy. |
  • | |
  • | INTERMEDIATE RISK |
  • | - Women 50-59 yrs, Men 40-59 yrs |
  • | - Smoking: 10 to 30 pack-years |
  • | - 11 to 25 RBCs/HPF on microscopy |
  • | ---> CLINICAL ACTION: RENAL ULTRASOUND + CYSTOSCOPY. |
  • | |
  • | HIGH RISK |
  • | - Women or Men >= 60 yrs |
  • | - Smoking: > 30 pack-years |
  • | - > 25 RBCs/HPF on microscopy |
  • | - History of GROSS HEMATURIA |
  • | - High-Risk Features: Occupational exposure to aromatic amines/dyes, |
  • | prior pelvic radiation, cyclophosphamide exposure, indwelling catheter. |
  • | ---> CLINICAL ACTION: MULTIPHASIC CT UROGRAPHY (CTU) + CYSTOSCOPY. |
  • +-----------------------------------------------------------------------------+

Multiphasic CT Urography (CTU): Gold-standard imaging modality for high-risk patients. Consists of: (1) Non-contrast phase (detects stones), (2) Nephrographic phase (detects renal parenchymal masses/RCC), and (3) Excretory delayed phase (opacifies renal pelvis, ureters, and bladder to identify filling defects and urothelial carcinoma).

Cystoscopy: Mandatory gold standard to directly inspect the bladder urothelium and urethra; cross-sectional imaging cannot reliably exclude flat or small bladder mucosal lesions ( carcinoma in situ ).